Ortin Laboratories Limited

As of December 31, 2023, Ortin Laboratories Limited trades at a trailing price-to-earnings ratio of 39.83.

As of December 31, 2023, Ortin Laboratories Limited trades at an EV/EBITDA multiple of 87.35 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.50 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 87.35 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Ortin Laboratories Limited trades at an EV/FCF ratio of 39.99, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of December 31, 2023, Ortin Laboratories Limited maintains a current ratio of 1.61, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 120.91, indicating elevated leverage, while an interest coverage ratio of -7.60 demonstrates limited ability to service its debt obligations.

Over the twelve months ended December 31, 2023, Ortin Laboratories Limited posted a gross margin of -30.46, reflecting its pricing power and cost economics. The operating margin of -104.69 and net profit margin of -119.76 provide insight into operational efficiency.

Ortin Laboratories Limited's most recent stock split took place on January 12, 2021 with a 25:12 split ratio.

As of December 31, 2023, Ortin Laboratories Limited has an Altman Z-Score of 1.60, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.